Ranta Annemarei, Chan Calvin, Rump Dorothea, Cariga Pietro, Anderson Lynley
Department of Neurology, MidCentral Health, Private Bag 11036, Palmerston North 4442, New Zealand.
N Z Med J. 2012 Jul 29;125(1358):35-43.
Stroke thrombolysis with alteplase is the most effective therapy for acute ischaemic stroke. Most trial data comes from tertiary centres. This study set out to assess safety and efficacy of thrombolysis at a secondary provincial centre in New Zealand.
A retrospective 3-year audit was performed to assess efficacy and safety of altepase at a secondary provincial hospital in New Zealand.
Out of 27 patients receiving treatment 17 (62.3%) improved and 10 (37.0%) enjoyed essentially complete symptom resolution (mRS=0 or 1). There was one symptomatic intracranial haemorrhage (3.7%).
Administration of intravenous alteplase for ischaemic stroke patients is effective and safe in the secondary provincial setting if local protocols are used, patient selection is stringent, and care is supervised by neurologists with training/experience in stroke care and thrombolysis. Aspects of thrombolysis-related management issues in this study population are discussed.
使用阿替普酶进行中风溶栓是急性缺血性中风最有效的治疗方法。大多数试验数据来自三级中心。本研究旨在评估新西兰一家省级二级中心进行溶栓治疗的安全性和有效性。
进行了一项为期3年的回顾性审计，以评估新西兰一家省级二级医院使用阿替普酶的有效性和安全性。
在接受治疗的27例患者中，17例（62.3%）病情改善，10例（37.0%）症状基本完全缓解（改良Rankin量表评分=0或1）。有1例症状性颅内出血（3.7%）。
如果使用当地方案、严格选择患者，并由具有中风护理和溶栓治疗培训/经验的神经科医生进行监督，在省级二级医院对缺血性中风患者静脉注射阿替普酶是有效且安全的。本文讨论了该研究人群中与溶栓相关的管理问题。
